Four groups recently reported the existence of an activating mutation of JAK2 in many patients with one of the classic myeloproliferative disorders (MPDs).[1][1]-[4][2] Mutant Janus kinase 2 (JAK2) has increased kinase activity, renders BaF3 cells cytokine independent, and produces erythrocytosis in
No takes yet. Share an insight, caveat, or question.
Scott et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: